ACAAI 2021

Researchers examined health disparities in the duration of asthma exacerbations in patients post-COVID-19.

A survey of allergists in North America and Europe explored how clinician attitudes towards cannabis affected discussions with patients regarding cannabis.

Can clinicians identify children who are at risk of developing a persistent wheeze?

In children with asthma, is excess weight linked to dysanapsis and PAI — and how do all 3 factors affect the risk of uncontrolled asthma?

Asthma control as measured by AIRQ may predict 12-month HRQoL, according to research reported at the 2021 ACAAI Annual Scientific Meeting.

A post hoc analysis of the QUEST trial assessed clinical remission in patients with moderate-to-severe asthma after 24 and 52 weeks of dupilumab treatment.

CHRONICLE trial findings offer a glimpse of the real-world outcomes of patients using benralizumab for severe asthma over a years’ time.

A prospective, single-center study examined the use of allergen immunotherapy for alleviating the burden of allergic rhinitis.

Research presented at ACAAI 2021 evaluated the efficacy of different biologic therapies in controlling asthma exacerbations in patients with varying BECs.

CHRONICLE investigators reported results of a patient survey on common asthma triggers at ACAAI 2021.